The value of digital health

Is health economics ready for digital transformation?

Katarzyna Kolasa, PhD, Dr.hab

Kozminski University, Poland

Helyszín Dátum

INVITATION

Corvinus Health Policy and Health Economics Conference Series 2020/1 Department of Health Economics, Corvinus University of Budapest in cooperation with: Health and Health Care Economics Section of the Hungarian Economic Association Health Economics Study Circle, Corvinus University of Budapest

Corvinus Health Policy and Health Economics Conference Series 2020/1

Corvinus University of Budapest, Faculty of Economics, Department of Health Economics,

in cooperation with: Health and Health Care Economics Section of the Hungarian Economic Association

Health Economics Study Circle, Corvinus University of Budapest

The value of digital health Is health economics ready for digital transformation?

Corvinus University of Budapest

February 25, 2020

Building C, Room IX 15:30-17:20

H-1093 Budapest, Fővám tér 13-15.1

Digital transformation in healthcare is reaching its tipping point. From the supporting infrastructure to medical devices, health data ecosystems, mobile health apps or wearable devices, the speed of development is accelerating year-by-year. Stakeholders including policymakers, health professionals, developers, investors as well as industry have high expectations about the benefits and saving digital health can deliver. Digital health can provide new insights to diseases, uncover new therapeutic effects, break down barriers to information or even access to care. The value of digital health seems so obvious, or is it? While the methods of demonstrating the value of traditional health technologies, such as pharmaceuticals are well established, the great variety and constant change of digital health technologies and the multitude of ways digital interventions impact health, patient experience or system efficiency pose challenges for health economists or decision-makers when assessing their value. This symposium will give insights into the latest developments and dilemmas in the health economic evaluation of digital health interventions. Our distinguished keynote speaker is Dr. Katarzyna Kolasa, PhD who is co-charing the Global Special Interest Group for Digital Health at ISPOR2. The Department of Health Economics, Corvinus University of Budapest will present research projects on digital health supported by the following grants3.

1 https://goo.gl/maps/CD1yKNj82QL2 2 The Professional Society for Health Economics and Outcomes Research 3 (a) Economic and Societal Benefits of Digitalisation in Healthcare, Project no. NKFIH-869-4/2019, implemented with the support provided from the National Research, Development and Innovation Fund of Hungary, financed under the Tématerületi Kiválósági Program 2019 funding scheme. (b) Higher Education Institutional Excellence Program of the Ministry of Human Capacities in the framework of the ‘Financial and Public Services’ research project (20764-3/2018/FEKUTSTRAT) at Corvinus University of Budapest. (c) Healthcare Performance Intelligence Professionals (HealthPros) – Marie Sklodowska-Curie Innovative Training Networks (MSCA-ITN-ETN), Call: H2020-MSCA-ITN-2017, Project ID: 765141

3

Conference chairperson: Prof. Márta Péntek, Department of Health Economics, Faculty of Economics, Corvinus University of Budapest

Program

15:30 – 15:40 Welcome - Prof. László Gulácsi, Head, Department of Health Economics, Corvinus University of Budapest

15:40 – 16:10 Dr. Katarzyna Kolasa, Head, Health Economics and Healthcare Management Division, Kozminski University,Warsaw, Poland; Co-Chair, ISPOR Digital Health Special Interest Group

Is health economics ready for digital transformation?

16:10-16:20 Csizmadia István, Chief Executive Advisor & Head of International Projects and Programs, National Healthcare Service Center (ÁEEK)

„Development directions and financing issues of digital health care in Hungary - with a special regard to the e-health digital service infrastructure, the co-operation in innovation and the cross-border ecosystem”

16:20-16:30 Merész Gergő, Head of Division for Health Technology Assessment, National Institute of Pharmacy and Nutrition (OGYÉI)

Critical assessment of digital health interventions submitted for reimbursement: local experience of learning by doing

16:30-16: 45 dr. Zsolt Szombathelyi, Advisor to the CEO, Gedeon Richter Plc.

Digital therapeutics New treatment modality on the horizon (?)

16:45-17:00 Oscar Brito Fernandes, HealthPros fellow, Department of Health Economics Corvinus University of Budapest; PhD student, University of Amsterdam

Can digital health strengthen citizen engagement in health care decision-making? A Marie-Skłodowska Curie HealthPros fellow viewpoint

17:00-17:15 dr. Zsombor Zrubka, Assistant professor, Department of Health Economics, Corvinus University of Budapest

Patient-reported outcomes in digital health

17:15 – 18:00 Discussion

18:00 Take home message & Closing

Prof. Márta Péntek, Department of Health Economics, Corvinus University of Budapest

4

Katarzyna Kolasa, PhD, Dr.hab Professor of Health Economics at Kozminski University Head of Health Economics and Healthcare Management Division Driven with the passion to health economics, Katarzyna Kolasa has acquired more than 20 years of academic and commercial experience with the pricing & reimbursement challenges of medical technologies. At Bristol Myers Squibb and Lundbeck she was leading Market Access teams in Central Eastern European (CEE) and Nordic Region. She was part of Global and Regional Health Economics & Outcomes Research (HEOR) teams at AstraZeneca and BiogenIdec being based in Sweden and Switzerland respectively. Her practical skills in the field of health economics were developed during six years employment contract at the Kalmar County Council in Sweden as well. For the last four years, she has been developing experience with the pricing &reimbursement challenges in the field of medical devices. Since 2016, Katarzyna has been representing Straub Medical as Global Market Access Lead being the External Principal Consultant for that Swiss family owned company. Prior to that, Katarzyna was employed as a Senior HEOR Director at GE Healthcare. She holds a PhD degree in health economics and is an author of more than 40 scientific IF publications in the field of health technology assessment, health economics and pharmacoeconomics. Katarzyna Kolasa reviews manuscripts submitted to such prestigious journals as Health Policy, Value in Health, Expert Review of Pharmacoeconomics & Outcomes Research, International Journal for Equity in Health and International Journal of Technology Assessment. Her extensive knowledge in the field of health economics was acquired at University of York, University of Lund, and University of Bergen as well as during International Doctoral Courses in Health Economics and Policy organized by the Swiss School of Public Health. Katarzyna Kolasa heads the Health Economics & Healthcare Management Division (HeM) at the Kozminski University. She is the leader of the International Master Program Health Economics & Big Data (HEBDA) financed by the National Center for Research and Development. HEBDA was granted the maximum amount of points across all applications of the POWER 2018 call. Among its partners, there are pharmaceutical companies, health data analytics providers as well as the Polish Ministry of Health and the Polish National Health Fund. HeM Division vision is to become the leading research center in Poland in the field of digital health in Europe. It collaborates closely with health economics partners from the University of Lund, the University of Athens, University of Illinois, University of York and the University of Applied Science in Berlin. Since January 2019, Katarzyna Kolasa is co-charing the Global Special Interest Group for Digital Health at ISPOR. In 2018, Katarzyna was nominated by the Ministry of Science to represent Poland in the COST Action CA17117, COST Association „Towards an International Network for Evidence-based Research in Clinical Health Research”.

5

Selected publications in scientific journals

1. Kolasa K et al Revealed preferences towards the appraisal of orphan drugs in Poland- MCDA analysis - Orphanet Journal of Rare Diseases 2018 13:67

2. Kolasa K Zwolinski K. Kalo Z and Hermanowski T Potential impact of the implementation of multiple-criteria decision analysis (MCDA) on the Polish pricing and reimbursement process of orphan drugs, Orphanet Journal of Rare Diseases 2016 11:23

3. Kolasa K Kalo Z Zah V The use of non-economic criteria in pricing and reimbursement decisions in Central and Eastern Europe: issues, trends and recommendations Expert Rev Pharmacoecon Outcomes Res. 2016,16 (4)

4. Does it matter whose opinion we seek regarding the allocation of healthcare resources? - a case study K. Kolasa T. Lewandowski BMC Health Services Research 2015

5. Are pricing and reimbursement decision-making criteria aligned with public preferences regarding allocation principles in the Polish healthcare sector? Expert Rev Pharmacoecon Outcomes Res. 2014 Oct;14(5):751-62

6. The paradox of public participation in the healthcare in Poland, - what citizens want, and what they think" Health Policy Kolasa K. Scibiorski C. Borek E. Siemiatkowski M. Published Online: October 01, 2014

7. Pricing and reimbursement frameworks in Central Eastern Europe: a decision tool to support choices Kolasa K. Kalo Z, Hornby E. Expert Rev Pharmacoecon Outcomes Res. 2014 Jun 26:1-11

8. Assessment of the attitudes of the general public towards supplementary criteria to be used in P&R decision making process in Poland- Kolasa K. Lees M Annemans L. International Journal of Technology Assessment in Health Care 2013

9. What aspects of HTA process recommended by international organizations did receive most attention in the appraisal process in Poland in the period 1/2007 – 9/2008? –Kolasa K, Dziomdziora M Fajutrao L, International Journal of Technology Assessment in Health Care, January 2011 27 : pp 84-94

6

István CSIZMADIA, MSc Chief Executive Advisor & Head of International Projects and Programs, National Healthcare Service Center (ÁEEK) István has extensive (30 years’) experience in a) Preparing, planning and managing EU funded programmes, b) Strategic planning, c) Preparing and submitting applications for EU grant, d) Implementing and coordinating EU projects, e) Evaluating applications and monitoring projects, f) Generating and providing support to innovation, cluster, logistic, transport, energy, environment and health programmes and projects, g) Working with international organizations e.g. EU COM, EU Council, UN organizations, h) Preparing and implementing bilateral and multilateral international agreements. Since June 2018 he has been the Work Package leader of WP5 ‘Innovative use of health data’ in the Joint Action supporting the eHealth Network (eHAction). Previously he used to be the representative of Hungary in the Programme Committee of the Third Health Programme 2014-2020 and the Steering Group on Health Promotion, Disease Prevention and Management of Non-Communicable Diseases (SGPP), as well as the Head of Subgroup2 for sharing and analysing experiences, best practices, to build up success factors for the effective use of Structural Funds for health investments in the Reflection Process On Modern, Responsive And Sustainable Health Systems (Council conclusions: Towards modern, responsive and sustainable health systems). He has Master's Degree in Health Management, professional qualification of Health Care Manager (2014) and Economics, professional qualification of transport and logistics (1989).

7

Gergő Merész, MsC Head of Division for Health Technology Assessment, National Institute of Pharmacy and Nutrition (OGYÉI) Gergő Merész owns a master’s degree in health policy with a specialization in health economics, and a bachelor’s degree in sociology. As a health economist, he is mainly focused on preparing systematic literature reviews, statistical analysis and programming, and data extraction from international health-related databases. As the head of department at the National Institute of Pharmacy and Nutrition’s Department of Health Technology Assessment, he supervises a team of medical and economic professionals who prepare the critical assessments of manufacturer-submitted reimbursement applications of health technologies. In his personal life, Gergő is a dog person and a committed cyclist.

8

dr. Zsolt Szombathelyi Advisor to the CEO at Gedeon Richter Plc. Zsolt has graduated as a medical doctor in 1981 at the Faculty of Medicine of Semmelweis Medical University, Budapest. Currently he is an advisor to the CEO at Gedeon Richter Plc. Before that he held several senior leadership positions at Gedeon Richter Plc., such as Chief Scientific Officer at the USA affiliate (2014-2018), Head of Research (2001-2014) and Head of Pharmacological and Drug Safety Research (1998-2000). He has also acted as the Representative Director of Medimpex Japan Co. Ltd, in Tokyo (1993-1998), as well as the 2nd secretary of the Commercial Section of the Hungarian Embassy in Tokyo, Japan (1992-1993). Prior his international endeavours, he started his career as a researcher pharmacologist at Gedeon Richter (1981-1992).

9

Prof. Márta Péntek, MD, PhD, Habil Professor, Department of Health Economics, Corvinus University of Budapest, Hungary. (http://hecon.uni-corvinus.hu) Márta works as a full and as a part-time senior consultant rheumatologist at the Department of Rheumatology, Flór Ferenc Hospital. She received Ph.D. degree from Semmelweis Medical University in Budapest (Thesis: Health status and disease burden of rheumatoid arthritis patients in Hungary), habilitated at 2013 in Pécs University. She is the president of the Health and Healthcare Economics Section of the Hungarian Economic Association. She is a member of the Editorial Board of the Health Economics Section of Frontiers in Public Health, Clinicoeconomics and Outcomes Research (ISSN: 1178-6981) and Immunológiai Szemle (ISSN: 2061-0203) journals. She has coordinated the Hungarian section of the EuroVaQ and BURQOL-RD international research projects funded by the European Commission and currently she is working in the HealthPros Marie Sklodowska-Curie Innovative Training Network. She has successfully supervised 4 PhD thesis and in the process of supervising another 2. To date she (co)authored 148 scientific articles in peer reviewed journals, published/edited 5 books, 18 bookchapters. Her publications were cited in 1455 cases. Her Hirsch index is 20. Her Google Scholar profile is available at: https://scholar.google.hu/citations?user=ZWupKeEAAAAJ&hl=hu&oi=ao

10

Prof. László Gulácsi MD, MSc. Ph.D. Ph.D., Ph.D. Ph.D., Habil. DSc. Head of Department of Health Economics, Corvinus University of Budapest, Hungary http://hecon.uni-corvinus.hu

By profession, László is a physician (Debrecen Medical University), having university degrees of programming mathematics (Kossuth Lajos University of Arts and Sciences, Debrecen), mathematical economics and sociology (Corvinus University of Budapest) and health economics (University of York, ARWU4 301-400). He received PhD degrees from the Medical University of Amsterdam (ARWU 101-150), Corvinus University of Budapest, Semmelweis Medical University in Budapest (ARWU 601-700) and from the Debrecen Medical University. He is qualified in social medicine. Habilitated at 2007 in Pécs University. He is a Doctor of the Hungarian Academy of Science since 2017. He is a member of the Standing Committee of Pharmacy, Hungarian Academy of Science. László Gulácsi is the past President of the Health and Health Care Economics Section of the Hungarian Economics Association. He is a member of the Editorial Board of the European Journal of Health Economics (IF:2,601), the Value in Health Regional Issues (SJR: 0.366) Editorial Advisory Board, the Editorial Board of the Hungarian Medical Journal (IF: 0,322, SJR: 0,16), and the Society and Economy, Health Academy, University of Pécs, Clinical Dermatology Open Access Journal, Associate Editorial and peer reviewer of Dove Medical press journals. He was a leader, coordinator or participant of 14 European Commission funded projects of the Department (Framework programmes, FP6, FP7, H2020). There are 2 ongoing H2020 programmes in the Department, between 2018-2022. To date (June 2019) he (co)authored 302 scientific articles in peer reviewed journals, published 12 books, 66 book chapters and on health economics, public health, health technology assessment, health policy and quality improvement. IF: 245,505. Citation: 1906 (1262). Hirsch index 24. Publications5 in the past 5 years and total: Q1: 46 (total: 67), D1: 18 (total: 20); Q2: 18 (total: 23); Q3: 10 (total:35); Q4: 6 (total: 10). He has successfully supervised 7 PhD thesis and in the process of supervising another 3. Publications: https://scholar.google.nl/citations?user=ek0KaHUAAAAJ&hl=en&oi=ao

4 ARWU: Academic Ranking of World Universities 5 https://www.scimagojr.com/

11

Óscar Brito Fernandes, MSc, MEd Óscar Brito Fernandes is a Marie-Skłodowska Curie Innovative Training Network for Healthcare Performance Intelligence Professionals fellow (HealthPros) based at the Department of Health Economics of Corvinus University of Budapest. He is currently pursuing a PhD at Amsterdam University Medical Centers, University of Amsterdam, where he is focusing on citizens engagement in health care purchasing by insurers. Óscar holds a bachelor’s degree in mathematics, a master’s in education and a master’s in healthcare management from National School of Public Health, NOVA University of Lisbon. During his studies and fellowship, he developed interests on health policy and health systems and services research.

12

Zsombor Zrubka MD, MBA, PhD Assistant professor Department of Health Economics, Corvinus University of Budapest, Hungary. Zsombor is a medical doctor, and prior joining the Department of Health Economics, he has gained 17 years of experience in the pharmaceutical industry in various national and international management roles at Pfizer, Egis Pharmaceuticals and Sandoz. As head of the International Biotechnology and Oncology Business Unit at Egis Pharmaceuticals Plc, he was the commercial lead of the introduction of the first biosimilar monoclonal antibody (infliximab) in the Central-Eastern European and CIS region. Zsombor has been the author / co-author of 14 scientific articles in peer-reviewed journals, with a total impact factor of 29.08. He has been cited 108 times (Google Scholar), and his Hirsch-index is 4. Currently he is coordinating the Thematic Excellence Research Project (TTKP) of the Corvinus University, sponsored by the National Research, Development and Innovation Office of Hungary including research programs in biotechnology and digital health. His Google Scholar profile is available at: https://scholar.google.hu/citations?user=Aos-sEIAAAAJ&hl=hu

13

Corvinus University of Budapest, Department of Health Economics Recent publications in scientific journals related to the conference topic 1: Rencz F, Tamási B, Brodszky V, Gulácsi L, Weszl M, Péntek M. Validity and reliability of the 9-item Shared Decision Making Questionnaire (SDM-Q-9) in a national survey in Hungary. Eur J Health Econ. 2019 Jun;20(Suppl 1):43-55. doi: 10.1007/s10198-019-01061-2. Epub 2019 May 20. PubMed PMID: 31111402; PubMed Central PMCID: PMC6544590. 2: Brodszky V, Beretzky Z, Baji P, Rencz F, Péntek M, Rotar A, Tachkov K, Mayer S, Simon J, Niewada M, Hren R, Gulácsi L. Cost-of-illness studies in nine Central and Eastern European countries. Eur J Health Econ. 2019 Jun;20(Suppl 1):155-172. doi: 10.1007/s10198-019-01066-x. Epub 2019 May 18. PubMed PMID: 31104219; PubMed Central PMCID: PMC6544593. 3: Zrubka Z, Beretzky Z, Hermann Z, Brodszky V, Gulácsi L, Rencz F, Baji P, Golicki D, Prevolnik-Rupel V, Péntek M. A comparison of European, Polish, Slovenian and British EQ-5D-3L value sets using a Hungarian sample of 18 chronic diseases. Eur J Health Econ. 2019 Jun;20(Suppl 1):119-132. doi: 10.1007/s10198-019-01069-8. Epub 2019 May 18. PubMed PMID: 31104218; PubMed Central PMCID: PMC6544595. 4: Zrubka Z, Golicki D, Prevolnik-Rupel V, Baji P, Rencz F, Brodszky V, Gulácsi L, Péntek M. Towards a Central-Eastern European EQ-5D-3L population norm: comparing data from Hungarian, Polish and Slovenian population studies. Eur J Health Econ. 2019 Jun;20(Suppl 1):141-154. doi: 10.1007/s10198-019-01071-0. Epub 2019 May 17. PubMed PMID: 31102159; PubMed Central PMCID: PMC6544754. 5: Lucevic A, Péntek M, Kringos D, Klazinga N, Gulácsi L, Brito Fernandes Ó, Boncz I, Baji P. Unmet medical needs in ambulatory care in Hungary: forgone visits and medications from a representative population survey. Eur J Health Econ. 2019 Jun;20(Suppl 1):71-78. doi: 10.1007/s10198-019-01063-0. Epub 2019 May 17. PubMed PMID: 31102157; PubMed Central PMCID: PMC6544592. 6: Brito Fernandes Ó, Baji P, Kringos D, Klazinga N, Gulácsi L, Lucevic A, Boncz I, Péntek M. Patient experiences with outpatient care in Hungary: results of an online population survey. Eur J Health Econ. 2019 Jun;20(Suppl 1):79-90. doi: 10.1007/s10198-019-01064-z. Epub 2019 May 16. PubMed PMID: 31098884; PubMed Central PMCID: PMC6544599. 7: Zrubka Z, Hajdu O, Rencz F, Baji P, Gulácsi L, Péntek M. Psychometric properties of the Hungarian version of the eHealth Literacy Scale. Eur J Health Econ. 2019 Jun;20(Suppl 1):57-69. doi: 10.1007/s10198-019-01062-1. Epub 2019 May 16. PubMed PMID: 31098883; PubMed Central PMCID: PMC6544600. 8: Rencz F, Gulácsi L, Drummond M, Golicki D, Prevolnik Rupel V, Simon J, Stolk EA, Brodszky V, Baji P, Závada J, Petrova G, Rotar A, Péntek M. EQ-5D in Central and Eastern Europe: 2000-2015. Qual Life Res. 2016 Nov;25(11):2693-2710. Epub 2016 Jul 29. Review. PubMed PMID: 27472992.